research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
Search
for
Sort by
Research
30 / 1000+ results 
research Study on the mechanism that SNPs related to sex hormone metabolism regulate the imbalance of sex hormones and lead to BPH in rats
Combined finasteride and anastrozole therapy effectively treats BPH, influenced by hormone imbalances and genetics.
research Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
research (192) Evaluating Effect of hCG and hCG+rFSH Therapy on Ejaculation Disorders in Middle-Aged Men: A Case Study
The therapies improved ejaculation disorders and sexual function in middle-aged men.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
research SUN-118 A Case of Anastrozole Induced Hyperandrogenism
Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.
research Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane
Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Bicalutamide
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
research Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
Bicalutamide may be a promising alternative treatment for female pattern hair loss.
research Abstract A12: Androgen receptor inhibition is involved in Finasteride-reduced AML cell proliferation
Finasteride reduces AML cell growth by inhibiting androgen receptors.
research A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
research The effects of oestrogens on linear bone growth
Oestrogens are key for bone growth during puberty in both boys and girls.
research Effect of estrogens on skin aging and the potential role of SERMs
Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research Emerging medication for the treatment of male hypogonadism
New treatments for male hypogonadism are effective and should be personalized.
research Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors
Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
research Aromatase inhibitor therapy and hair loss among breast cancer survivors
Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.
research The effects of oestrogens on linear bone growth
Estrogens are key for bone growth spurts in both boys and girls and affect growth into adulthood.
research Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study
Integrating best practices for steroid users in Swiss primary care is feasible and beneficial, but doping laws need change.
research Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview
Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
research Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations
Clinicians should use social and prescription data to track trends in performance-enhancing drug use.